

*Strategies  
and Tactics  
in Organic  
Synthesis*

*Volume 11*

Edited by  
MICHAEL HARMATA



# Strategies and Tactics in Organic Synthesis


---

Volume 11

Edited by

**Michael Harmata**

University of Missouri – Columbia



ELSEVIER

AMSTERDAM • BOSTON • HEIDELBERG • LONDON  
NEW YORK • OXFORD • PARIS • SAN DIEGO  
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier  
125, London Wall, EC2Y 5AS  
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK  
225 Wyman Street, Waltham, MA 02451, USA  
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA

First edition 2015

© 2015 Elsevier Ltd. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

#### Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, editors, or editorial board members assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-08-100023-6  
ISSN: 1874-6004

For information on all Academic Press publications  
visit our web site at [store.elsevier.com](http://store.elsevier.com)

Printed in the United States of America



Working together  
to grow libraries in  
developing countries

[www.elsevier.com](http://www.elsevier.com) • [www.bookaid.org](http://www.bookaid.org)

# Strategies and Tactics in Organic Synthesis

Volume 11

## EDITORIAL BOARD

**Professor Erik J. Sorensen**

Department of Chemistry  
Frick Laboratory  
Princeton University  
Washington Road  
Princeton, NJ, USA

**Professor Dirk Trauner**

Department Chemie und Biochemie  
Ludwig-Maximilians-Universität München  
Butenandtstr. 5-13, Haus F  
München, Germany

**Professor Frederick G. West**

Department of Chemistry  
University of Alberta  
Gunning-Lemieux Chemistry Centre E3-43  
Edmonton, Alberta  
Canada

**Professor Craig M. Williams**

School of Chemistry and Molecular Biosciences  
University of Queensland Brisbane  
Queensland, Australia

**Professor Pauline Chiu**

Department of Chemistry  
The University of Hong Kong  
Pokfulam Road, Hong Kong

**Dr. Jean Suffert**

Université de Strasbourg  
Faculté de Pharmacie  
Laboratoire d'Innovation Thérapeutique  
Equipe SOMP  
(UMR 7200 CNRS/UDS)  
Illkirch Cedex, France

*Life has a way of confusing us,  
Blessing and bruising us.  
Drink, l'chaim, to life!*

**from Fiddler on the Roof**



# Contributors

*Numbers in Parentheses indicate the pages on which the author's contributions begin.*

**Aaron Aponick** (1), Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, Florida, USA

**Janick Ardisson** (51), Faculté de Pharmacie, CNRS UMR 8638, Université Paris Descartes, Paris Cedex, France

**Martin G. Banwell** (29), Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, Australian Capital Territory, Australia

**Jean-François Betzer** (51), Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Gif-sur-Yvette, France

**Nicolas Blanchard** (85), Laboratoire de Chimie Moléculaire, Université de Strasbourg, Strasbourg Cedex, France

**Margaret A. Brimble** (119), School of Chemical Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand

**Lise Bréthous** (85), Laboratoire de Chimie Moléculaire, Université de Strasbourg, Strasbourg Cedex, France

**Joshua N. Buckler** (29), Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, Australian Capital Territory, Australia

**Barry B. Butler Jr.** (1), Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, Florida, USA

**Lisa Candish** (309), School of Chemistry, Monash University, Melbourne, Victoria, Australia

**Virginie Casarotto** (85), Laboratoire de Chimie Moléculaire, Université de Strasbourg, Strasbourg Cedex, France

**Anne-Caroline Chany** (85), Laboratoire de Chimie Moléculaire, Université de Strasbourg, Strasbourg Cedex, France

**Ke Chen** (171), Chemical Development, Bristol-Myers Squibb Co., New Brunswick, New Jersey, USA

**Brenton DeBoef** (151), Department of Chemistry, University of Rhode Island, Kingston, Rhode Island, USA



- Cristian Draghici** (335), Department of Chemistry & Biochemistry, University of Arizona, Tucson, Arizona, USA
- Martin Eastgate** (171), Chemical Development, Bristol-Myers Squibb Co., New Brunswick, New Jersey, USA
- Daniel. P. Furkert** (119), School of Chemical Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand
- Nicolas Girard** (235), Faculté de Pharmacie, Laboratoire d'Innovation Thérapeutique, CNRS-Université de Strasbourg, Illkirch, France
- Andrew M. Harned\*** (253), Department of Chemistry, University of Minnesota, Minneapolis, Minnesota, USA
- Paul A. Hume** (119), School of Chemical Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand
- Colin J. Jackson** (29), Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, Australian Capital Territory, Australia
- Ping Lan** (29), Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, Australian Capital Territory, Australia
- David W. Lupton** (309), School of Chemistry, Monash University, Melbourne, Victoria, Australia
- Xinghua Ma** (29), Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, Australian Capital Territory, Australia
- Eliška Matoušová** (29), Department of Organic Chemistry, Faculty of Science, Charles University in Prague, Praha, Czech Republic
- Jon T. Njardarson** (335), Department of Chemistry & Biochemistry, University of Arizona, Tucson, Arizona, USA
- Jeremy Nugent** (29), Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, Australian Capital Territory, Australia
- Yong Qin** (377), West China School of Pharmacy, Sichuan University, Chengdu, PR China
- Christina Risatti** (171), Chemical Development, Bristol-Myers Squibb Co., New Brunswick, New Jersey, USA
- Sarah Saint-Auret** (85), Laboratoire de Chimie Moléculaire, Université de Strasbourg, Strasbourg Cedex, France
- Hao Song** (377), West China School of Pharmacy, Sichuan University, Chengdu, PR China
- Cédric Tresse** (85), Laboratoire de Chimie Moléculaire, Université de Strasbourg, Strasbourg Cedex, France

---

\*Present Address: Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, USA

**Kelly A. Volp**<sup>†</sup> (253), Department of Chemistry, University of Minnesota, Minneapolis, Minnesota, USA

**Dan Zhang** (377), West China School of Pharmacy, Sichuan University, Chengdu, PR China

---

<sup>†</sup>Present Address: 3M, Corporate Research Materials Laboratory, St. Paul, Minnesota, USA



# Preface

Given that I have a propensity for dedicating books in this series to people who have died, mostly because so many good folks have a propensity for dying, I decided to move in a different direction for this volume. In the past year, we have had storms, plane crashes, miscellaneous disasters, and the especially painful display of people who murder using the reason or excuse that they are doing the work of a god. Plainly said, it sucks. But, I remember from forays into philosophy in my youth something mentioned by Pierre Teilhard de Chardin: “No matter what reactions we may have to current events, we ought to first reaffirm a robust faith in the destiny of man.” Easy for him to say! Still, science and labs do not insulate us from the world. Like it or not, we are part of the whole ball of wax. There’s a lot that has to be done to keep it rolling, in science and elsewhere. To life!

It is always a pleasure to edit these volumes, primarily because I get to work with many wonderful colleagues and rediscover their work in a very up-close way. Indeed, I say rediscover as I suffer from OIDS (Offspring-Induced Dementia Syndrome) and have a predilection for forgetting stuff I didn’t used to forget. Though I am probably preaching to the choir, I think it is always important to emphasize that synthetic organic chemistry, whether focused on preparing a specific target(s) or developing new methodology, is the epitome of human activity in terms of both intellect and passion. Sing that from the mountaintops and give high praise to all those involved in such adventures!

I must, as per usual, thank Elsevier for their continued commitment to this series, through thick and thin. My special thanks to Derek Coleman and Susan Dennis for their help and support over the years.

Finally, I want to express my gratitude to the Editorial Board. These colleagues are the wonderful folks who help me tremendously in securing authors for this publication. Their being part of the “team” is an asset that I truly value. I look forward to many more years of work with them.

MICHAEL HARMATA



# Contents

Contributors	xv
Preface	xix

<b>1. Acortatarin A: Spiroketalization Methods and Synthesis</b>	<b>1</b>
<i>Barry B. Butler Jr. and Aaron Aponick</i>	
1 Introduction	1
2 Evolution of Au- and Pd-Catalyzed Spiroketalization Methods	3
2.1 Au-Catalyzed Allylic Substitution	3
2.2 Au-Catalyzed Spiroketalization of Propargylic Triols and Acetonides	4
2.3 Pd-Catalyzed Spiroketalization: An Interrupted Allylic Substitution	7
3 Acortatarin A and Related Natural Products	8
3.1 Introduction	8
3.2 Biological Activity	9
3.3 Structural Analysis	11
3.4 First Synthesis of Acortatarins A and B	12
3.5 Acid-Catalyzed Spiroketalization	16
3.6 Stereoselective Glycal Cyclization	19
4 Synthetic Efforts via Pd-Catalyzed Spiroketalization	20
4.1 Retrosynthesis	21
4.2 Synthesis of Key Intermediates	22
4.3 Spiroketalization and Completion of the Synthesis of Acortatarin A	23
5 Conclusion	25
Acknowledgments	25
References	25

<b>2. Devising New Syntheses of the Alkaloid Galanthamine, a Potent and Clinically Deployed Inhibitor of Acetylcholine Esterase</b>	<b>29</b>
<i>Martin G. Banwell, Joshua N. Buckler, Colin J. Jackson, Ping Lan, Xinghua Ma, Eliška Matoušová, and Jeremy Nugent</i>	
1 Introduction	29
2 Studies on the Synthesis of Galanthamine—A Potted History	31

3	A First-Generation Chemoenzymatic Synthesis of (+)-Galanthamine	33
4	Total Syntheses of Members of the Ribisin Class of Neurologically Active Natural Product Inspire a Second-Generation Chemoenzymatic Approach to (+)-Galanthamine	37
4.1	The Ribisins	37
4.2	A Second-Generation Chemoenzymatic Approach to the Synthesis of (+)-Galanthamine	40
5	An Abortive, Radical-Based Approach to (±)-Galanthamine	42
6	Doing Things the Hard Way— <i>De Novo</i> Construction of the Aromatic C-Ring as a Focal Point	44
7	Conclusions	47
	Acknowledgments	48
	References	48
3.	<b>Discodermolide: Total Synthesis of Natural Product and Analogues</b>	51
	<i>Jean-François Betzer and Janick Ardisson</i>	
1	Introduction	51
2	Synthetic Approach and Synthetic Methods Development	53
2.1	Reactivity of an $\alpha$ -Oxygenated Crotyltitanium	54
2.2	Reactivity of a Z-O-Enecarbamate Group	57
2.3	1,2-Dyotropic Rearrangement of Dihydrofuran	59
3	Total Synthesis of (+)-DDM	62
3.1	Strategic Considerations	62
3.2	Preparation of C8–C14 Subunit B	62
3.3	Preparation of C15–C24 Subunit A	66
3.4	Preparation of C1–C7 Subunit C	67
3.5	Completion of Total Synthesis of DDM	68
4	Conception, Synthesis, and Biological Evaluation of DDM Analogues	69
4.1	Conformation of DDM and Conception of Analogues	69
4.2	Modification of Terminal Diene C15–C24 Part	73
4.3	Modification of the Trisubstituted C13–C14 Double Bond	75
4.4	Modification of C1–C5 Lactone Part	76
4.5	Biological Evaluation of Synthetic Analogues	77
5	Conclusion	79
	Acknowledgments	79
	References	79
4.	<b>A Walk Across Africa with Captain Grant: Exploring <i>Mycobacterium ulcerans</i> Infection with Mycolactone Analogs</b>	85
	<i>Nicolas Blanchard, Anne-Caroline Chany, Cédric Tresse, Virginie Casarotto, Lise Bréthous, and Sarah Saint-Auret</i>	
1	Introduction	85

2	<b>Synthetic Strategy of the Mycolactone A/B Analogs</b>	90
2.1	Retrosynthetic Analysis	90
2.2	Synthesis of the C1–C20 Fragment	91
2.3	Synthesis of the C1'–C16' Fragment	98
2.4	Completion of the Synthesis and Overview of the Panel of Analogs	106
3	<b>Exploration of the Biology Induced by Mycolactone A/B Analogs</b>	111
4	<b>Conclusions and Future Prospects</b>	113
	<b>Acknowledgments</b>	116
	<b>References</b>	116
5.	<b>Total Synthesis of the Fungal Metabolite Virgatolide B</b>	119
	<i>Paul A. Hume, Daniel. P. Furkert, and Margaret A. Brimble</i>	
1	<b>Introduction</b>	119
2	<b>First Synthetic Strategy</b>	123
2.1	First-Generation Retrosynthetic Analysis	123
2.2	Suzuki Cross-Coupling	124
2.3	Diastereoselective Aldol Reaction	126
2.4	Attempted Spiroketalization	127
3	<b>Second Synthetic Strategy</b>	130
3.1	Second-Generation Retrosynthetic Analysis	130
3.2	Suzuki Cross-Coupling	132
3.3	Aldol Reaction	135
3.4	Spiroketalization	137
4	<b>Total Synthesis of Virgatolide B</b>	139
4.1	Final Retrosynthetic Analysis	139
4.2	Asymmetric Dihydroxylation and Iodination	142
4.3	Carboalkoxylation	144
4.4	Final Elaboration to Virgatolide B	146
5	<b>Conclusion</b>	147
	<b>Acknowledgments</b>	149
	<b>References</b>	149
6.	<b>The Role of Design, Serendipity, and Scientific Competition in the Development of Oxidative Coupling Reactions</b>	151
	<i>Brenton DeBoef</i>	
1	<b>Introduction</b>	152
2	<b>Synthesis of Biaryls via Oxidative Cross-Coupling</b>	153
2.1	Initial Attempts at Oxidative Amination: Scooped Before We Even Started	153
2.2	Serendipitous Discovery	154
2.3	Lead Development and Optimization	155
2.4	Scooped Again	157
3	<b>Controlling Regioselectivity for Indole Substrates</b>	157
3.1	Oxidant-Controlled Regioselectivity	157



3.2	"pH" Adjusted Conditions for <i>N</i> -Alkylindoles	158
3.3	Application to the Synthesis of a Botulinum Neurotoxin Inhibitor	160
4	<b>Mechanism of C–H Palladation in Oxidative Coupling Reactions</b>	161
4.1	CMD Pathways for Both C–H Palladations	161
4.2	Pd(II)/Pd(IV) for Reactions Oxidized by $\text{H}_4\text{PMo}_{11}\text{VO}_{40}/\text{O}_2$	162
5	<b>Returning to Oxidative Amination</b>	162
5.1	Design of a I(III)-Mediated C–H Amination and the Continuing Role of Serendipity	163
5.2	Competition and Differing Mechanistic Interpretations	164
5.3	Second-Generation Oxidative Aminations: Regioselectivity as a Function of Mechanism	166
6	<b>Conclusion</b>	168
	<b>Acknowledgements</b>	168
	<b>References</b>	169
7.	<b>Overcoming Electronics with Strategy: Development of an Efficient Synthesis of the HIV Attachment Inhibitor Prodrug, BMS-663068</b>	171
	<i>Ke Chen, Christina Risatti, and Martin Eastgate</i>	
1	<b>Introduction</b>	171
1.1	Original Route	173
1.2	Endgame Modification	178
2	<b>Route Selection</b>	182
2.1	Assembly of 6-Azaindole Core	182
2.2	Installation of the Triazole: Overcoming Reactivity and Regioselectivity Issues	193
2.3	Introduction of the C3 Side Chain	202
2.4	Assessment	208
2.5	Endgame: Isolation of <b>2</b> and Prodrug Installation	211
3	<b>Lessons Discovered During Process Development</b>	215
3.1	Azaindole Core: Aromatization and Methoxylation	217
3.2	C7 Bromination: PyBrop and Reissert	219
3.3	Triazole Incorporation: Ullmann Coupling	224
4	<b>Conclusion</b>	229
	<b>Acknowledgments</b>	230
	<b>References</b>	231
8.	<b>Synthesis of Alkaloids Containing a Quinolizidine Core by Means of Strategies Based on a Hydroformylation Reaction</b>	235
	<i>Nicolas Girard</i>	
1	<b>Introduction</b>	235
2	<b>Aza-Sakurai–Hosomi Reaction Associated with Hydroformylation</b>	238